← ANALYST RATINGS · TIPRANKS
Arcturus Therapeutics (ARCT): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy2 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $21.29, the highest $41.00, the lowest $9.00. The average is +105.9% from the last price of $10.34.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.50 → $11.50−8.0% | Hold | +11.2% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $11.00−4.3% | Hold | +6.4% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.50 → $11.50−8.0% | Hold | +11.2% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.00 → $11.00−8.3% | Hold | +6.4% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.50 → $11.50−8.0% | Hold | +11.2% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.00 → $11.00−8.3% | Hold | +6.4% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| Unknown Analyst | Leerink Partners | $13.00 → $19.00+46.2% | Buy | +83.8% | Assigned | 09.10.26on TipRanks 21:02 | −8.2%next day −4.6% | ↗ |
| Unknown Analyst | Wells Fargo | $20.00 | Buy | +93.4% | Reiterated | 02.10.26on TipRanks Oct 9 21:02 | −2.1%next day +11.8% · 5 days +4.3% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $20.00 | Buy | +93.4% | Reiterated | 01.10.26on TipRanks Oct 2 06:16 | −3.7%next day −2.1% · 5 days −3.9% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 24.09.26on TipRanks 10:15 | +6.2%next day −2.5% · 5 days −6.0% | ↗ |
| Adam Walsh★★★★★★★★★★#4262 · hits 43% · avg +4.4% | Roth MKM | $41.00 | Buy | +296.5% | Reiterated | 24.09.26on TipRanks 09:45 | +6.2%next day −2.5% · 5 days −6.0% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $20.00 | Buy | +93.4% | Reiterated | 24.09.26on TipRanks 07:07 | +6.2%next day −2.5% · 5 days −6.0% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $9.00 | Hold | −13.0% | Reiterated | 24.09.26on TipRanks 06:25 | +6.2%next day −2.5% · 5 days −6.0% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $20.00 | Buy | +93.4% | Upgrade | 24.09.26on TipRanks 05:30 | +6.2%next day −2.5% · 5 days −6.0% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | — | Hold | — | Reiterated | 06.08.26on TipRanks Aug 7 08:01 | −2.7%next day +21.3% · 5 days +28.1% | ↗ |
| Ilya Zubkov★★★★★★★★★★#5009 · hits 59% · avg +9.5% | Freedom Capital Markets | $27.00 | Buy | +161.1% | Initiated | 02.07.26on TipRanks 05:35 | +5.8%next day +0.1% · 5 days −5.6% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $22.00 | Buy | +112.8% | Initiated | 18.03.26on TipRanks 05:10 | +3.9%next day +2.8% · 5 days +8.2% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $72.00 → $25.00−65.3% | Buy | +141.8% | Reiterated | 04.03.26on TipRanks 07:40 | −4.9%next day −3.8% · 5 days −0.3% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $20.00 | Buy | +93.4% | Reiterated | 04.03.26on TipRanks 07:40 | −4.9%next day −3.8% · 5 days −0.3% | ↗ |
| Lili (Aurélie) Nsongo★★★★★★★★★★#12236 · hits 10% · avg −32.8% | Leerink Partners | $54.00 → $17.00−68.5% | Buy | +64.4% | Reiterated | 23.10.25on TipRanks Oct 24 09:15 | +3.4%next day −7.3% · 5 days −21.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Arcturus Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.00 at a price of $13.69 (+60.7%); now: $21.29 at $10.34 (+105.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 3 | 5 | 7 | 9 | 9 |
| Buy | 3 | 2 | 3 | 3 | 7 | 6 |
| Hold | 5 | 2 | 2 | 2 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.69 (from $-0.92 to $-0.29). Last quarter: $-0.84.
Sales
Next quarter’s sales estimate — $8M (from $2M to $16M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Arcturus Therapeutics
- CEO: Joseph E. Payne
- Employees: 109
- 10628 Science Center Drive, San Diego, CA, 92121, US
- arcturusrx.com
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Data from the stock’s TipRanks forecast page, read 46 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗